Detalhe da pesquisa
1.
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.
N Engl J Med
; 382(2): 140-151, 2020 01 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31914241
2.
NPM1 and FLT3-TKD mutations are enriched in patients with leukemia cutis.
Dermatol Online J
; 26(7)2020 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32898396
3.
Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts.
Blood
; 140(20): 2170-2174, 2022 11 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-35797468
4.
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.
Lancet Oncol
; 18(8): 1061-1075, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28645776
5.
Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS).
Haematologica
; 101(6): 781-8, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26944474
6.
A Phase I dose-escalation study of DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1) in patients with acute myeloid leukemia.
Am J Hematol
; 96(5): E175-E179, 2021 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33617672
7.
Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid.
Blood
; 118(5): 1248-54, 2011 Aug 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-21653939
8.
Randomized phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia.
Haematologica
; 98(1): 119-28, 2013 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-22801961
9.
Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML.
Blood Adv
; 7(13): 3117-3127, 2023 07 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36724515
10.
Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study.
J Clin Oncol
; 41(15): 2815-2826, 2023 05 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36888930
11.
Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML.
J Clin Oncol
; 41(26): 4236-4246, 2023 09 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37379495
12.
Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML.
Blood Adv
; 7(9): 1858-1870, 2023 05 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36477975
13.
A Transcriptome-Based Precision Oncology Platform for Patient-Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies.
Cancer Discov
; 13(6): 1386-1407, 2023 06 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37061969
14.
Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-Lintuzumab.
Clin Cancer Res
; 28(10): 2030-2037, 2022 05 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-35247915
15.
A phase 1b study of atezolizumab in combination with guadecitabine for the treatment of acute myeloid leukemia.
Leuk Lymphoma
; 63(9): 2180-2188, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35491816
16.
Targeted Alpha-Particle Therapy for Hematologic Malignancies.
Semin Nucl Med
; 50(2): 152-161, 2020 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-32172800
17.
Rewriting the rules for care of MDS and AML patients in the time of COVID-19.
Leuk Res Rep
; 13: 100201, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32318330
18.
Targeted Alpha-Particle Therapy for Hematologic Malignancies.
J Med Imaging Radiat Sci
; 50(4 Suppl 1): S53-S57, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31253514
19.
Clinical Studies with Bismuth-213 and Actinium-225 for Hematologic Malignancies.
Curr Radiopharm
; 11(3): 192-199, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29793418
20.
Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia.
Blood Adv
; 2(3): 224-234, 2018 02 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-29386195